Thursday, November 12, 2026

Corn Futures Bullish Momentum With A 4% Rise In The Last 5 Sessions

Corn Futures Bullish Momentum With A 4% Rise In The Last 5 Sessions

(VIANEWS) - Corn (ZC) has been up by 4.63% for the last 5 sessions. At 23:54 EST on Monday, 8 April, Corn (ZC) is $446.25.

Volume

Today's last reported volume for Corn is 3341, 97.48% below its average volume of 132785.6.

Volatility

Corn's last week, last month's, and last quarter's current intraday variation average was a negative 0.79%, a negative 0.33%, and a positive 2.49%, respectively.

Corn's highest amplitude of average volatility was 0.79% (last week), 0.69% (last month), and 2.49% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Corn's commodity is considered to be overbought (>=80).

News about

  • Crude oil forecast: continues to power higher - 08 April 2024. According to DailyForex on Monday, 8 April, "The West Texas Intermediate Crude Oil market initially pulled back during the day on Friday as we were waiting for the jobs number. ", "At this point, I fully anticipate that the WTI Crude Oil marketers looking to the $87.50 level next, followed by the $90 level above."
  • According to FXStreet on Monday, 8 April, "The optimism is being fueled by positive economic data from China - the world's top importer - and supports prospects for the emergence of some dip-buying around Crude Oil prices.", "Apart from this, the OPEC+ clampdown on some countries to increase compliance with output cuts, along with a strong demand outlook, acts as a tailwind for Crude Oil prices. "

More news about Corn (ZC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com